Data evaluating the long-term efficacy and safety of Tribenzor (olmesartan medoxomil, amlodipine besylate, plus hydrochlorothiazide) in patients with hypertension aged 65 years and older showed that the triple therapy was well-tolerated and effective in maintaining the blood pressure reductions, regardless of age, race, or diabetes status.
The pre-specified subgroup analysis results, presented at the American Society of Hypertension, Inc. (ASH) 26th Annual Scientific Meeting and Exposition, found that a similar percentage of patients treated with the triple therapy achieved BP goal in both age groups. The triple therapy was well-tolerated in both age groups and most adverse events (AE) were mild or moderate in severity.
“Older patients generally have a more difficult time achieving recommended blood pressure levels and as a result, their hypertension often remains uncontrolled,” said Suzanne Oparil, MD, professor of medicine and physiology and biophysics at the University of Alabama School of Medicine. “However this analysis shows that long-term blood pressure control can be achieved safely and effectively across all studied dosing strengths with a triple combination therapy regardless of age. This is important given the fact that more than 64% of men and 75% of women 70 years or older have high blood pressure.”
Release Date: May 23, 2011
Source: Daiichi Sankyo Group
Filed Under: Drug Discovery
